Identification and treatment of osteoporosis in fractures

Current Rheumatology Reports

Volumn 5, Issue 1, 2003, Pages 57-64

  McLellan, Alastair R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Alendronate; Bone Mineral Density; Fracture Risk; Osteoporotic Fracture; Vertebral Fracture

Indexed keywords

FEMALE; FRACTURE; HUMAN; MALE; OSTEOPOROSIS; RECURRENT DISEASE; REVIEW; RISK;

FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; RECURRENCE; RISK;

EID: 0037946798     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-003-0084-7     Document Type: Article

References (40)

1. Keene GS, Parker MJ, Pryor GA: Mortality and morbidity after hip fractures. BMJ 1993, 307:1248–1250.
2. Huang C, Ross PD, Wasnich RD: Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 2003, 156:2469–2475. DOI: 10.1001/archinte.156.21.2469
3. Huang C, Ross PD, Wasnich RD: Vertebral fractures and other predictors of back pain among older women. J Bone Miner Res 2003, 11:1026–1032.
4. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878–882. A study from Australia that shows that fractures are associated with increased mortality compared with the general population; the mortality in men with fractures is higher than in women with fractures. DOI: 10.1016/S0140-6736(98)09075-8
5. Ensrud KE, Thompson DE, Cauley JA, et al.: Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000, 48:241–249.
6. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610. The first randomized, placebo-controlled intervention trial in men with osteoporosis that shows fracture risk reduction with alendronate of similar magnitude to fracture risk reduction in women. DOI: 10.1056/NEJM200008313430902
7. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 2003, 348:1535–1541. DOI: 10.1016/S0140-6736(96)07088-2
8. Pols HA, Felsenberg D, Hanley DA, et al.: Multinational, placebocontrolled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999, 9:461–468. Randomized, placebo-controlled trial of alendronate in women with low BMD showing significant efficacy in reducing incidence of nonvertebral fractures. DOI: 10.1007/PL00004171
9. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077–2082. DOI: 10.1001/jama.280.24.2077
10. Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437–1443. DOI: 10.1056/NEJM199511303332201
11. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344–1352. A double blind, randomized, placebo-controlled trial that shows that risedronate can reduce the incidence of vertebral and nonvertebral fractures in women with multiple vertebral fractures. DOI: 10.1001/jama.282.14.1344
12. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83–91. Randomized, placebo-controlled trial that shows that risedronate can reduce the incidence of vertebral fracture in women with osteoporosis. DOI: 10.1007/s001980050010
13. McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333–340. The first randomized, placebo-controlled trial of bisphosphonate therapy in women with osteoporosis, with hip fracture reduction as the primary endpoint. Showed that, if risedronate was targeted on basis of low BMD, bisphosphonate therapy could reduce hip fracture incidence. Hip fracture reduction is not seen if treatment is targeted on basis of non-BMD fracture risk factors. DOI: 10.1056/NEJM200102013440503
14. Watts NB, Harris ST, Genant HK, et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73–79. DOI: 10.1056/NEJM199007123230201
15. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637–645. Randomized, placebo-controlled trial of the first selective estrogen receptor modulator in women with osteoporotic fractures. Fracture efficacy is restricted to vertebral fracture risk reduction. DOI: 10.1001/jama.282.7.637
16. Chesnut CH III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267–276.
17. Kanis JA, Delmas P, Burckhardt P, et al.: Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997, 7:390–406. DOI: 10.1007/BF01623782
18. Royal College of Physicians: Clinical guidelines for the prevention and treatment of osteoporosis. London: Royal College of Physicians Press; 1999.
19. Klotzbuecher CM, Ross PD, Landsman PB, et al.: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721–739. DOI: 10.1359/jbmr.2000.15.4.721
20. van Staa TP, Leufkens HG, Cooper C: Does a Fracture at one site predict later fractures at other sites? A British Cohort Study. Osteoporos Int 2002, 13:624–629. A study that gives further insight into the risk of fractures at any site after a previous fracture at any site. This increased fracture risk holds true in postmenopausal women, premenopausal women, and in men. Provides useful actual 5-year fracture risks after fracture at different ages. DOI: 10.1007/s001980200084
21. Hosmer WD, Genant HK, Browner WS: Fractures before menopause: a red flag for physicians. Osteoporos Int 2002, 13:337–341. DOI: 10.1007/s001980200035
22. Wu F, Mason B, Horne A, et al.: Fractures between the ages of 20 and 50 years increase women’s risk of subsequent fractures. Arch Intern Med 2002, 162:33–36. DOI: 10.1001/archinte.162.1.33
23. Melton LJ III, Atkinson EJ, Cooper C, et al.: Vertebral fractures predict subsequent fractures. Osteoporos Int 1999, 10:214–221. DOI: 10.1007/s001980050218
24. Kotowicz MA, Melton LJ III, Cooper C, et al.: Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994, 9:599–605. DOI: 10.1002/jbmr.5650090503
25. Ismail AA, Cockerill W, Cooper C, et al.: Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001, 12:85–90. DOI: 10.1007/s001980170138
26. Johnell O, Oden A, Caulin F, Kanis JA: Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 2001, 12:207–214. A study that highlights the early increased risk of fractures seen after discharge after vertebral fracture requiring hospitalization. In reality, few patients with vertebral fractures are admitted, but they are at very high risk of early, further fractures. DOI: 10.1007/s001980170131
27. Kanis JA, McCloskey EV: Epidemiology of vertebral osteoporosis. Bone 1992, 13(suppl):S1-S10. DOI: 10.1016/8756-3282(92)90189-4
28. Doherty DA, Sanders KM, Kotowicz MA, Prince RL: Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 2001, 12:16–23. Important study that adds useful information about lifetime fracture risk. DOI: 10.1007/s001980170152
29. Nolla JM, Gomez-Vaquero C, Fiter J, et al.: Usefulness of bone densitometry in postmenopausal women with clinically diagnosed vertebral fractures. Ann Rheum Dis 2002, 61:73–75. Study confirming the high prevalence of osteoporosis in patients presenting with clinical vertebral fractures. DOI: 10.1136/ard.61.1.73
30. Cuddihy MT, Gabriel SE, Crowson CS, et al.: Osteoporosis intervention following distal forearm fractures. Arch Intern Med 2002, 162:421–426. DOI: 10.1001/archinte.162.4.421
31. Torgerson DJ, Dolan P: Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998, 57:378–379. DOI: 10.1136/ard.57.6.378
32. Juby AG, Geus-Wenceslau CM: Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002, 13:205–210. DOI: 10.1007/s001980200015
33. McLellan AR, Fraser M: A 28-month audit of the efficacy of the fracture liaison service in offering secondary prevention for patients with osteoporotic fractures [abstract]. J Bone Miner Res 2002, 17:S385.
34. Lufkin EG, Wahner HW, O’Fallon WM, et al.: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1–9.
35. Schnitzer T, Bone HG, Crepaldi G, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000, 12:1–12.
36. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321–333. Study that defines the risks and benefits of hormone replacement therapy use in normal, healthy postmenopausal women. Confirms that, even in normal women, 5 years of hormone replacement can reduce the incidence of hip and other fractures. Overall, with 5 years of hormone replacement therapy, the risks may outweigh the benefits. DOI: 10.1001/jama.288.3.321
37. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ: Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994, 308:1081–1082.
38. Diamond TH, Thornley SW, Sekel R, Smerdely P: Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997, 167:412–415.
39. Forsen L, Sogaard AJ, Meyer HE, et al.: Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999, 10:73–78. DOI: 10.1007/s001980050197
40. Selby PL, Davies M, Adams JE: Do men and women fracture bones at similar bone densities? Osteoporos Int 2000, 11:153–157. DOI: 10.1007/PL00004177